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Platinum(II)-based DNA intercalators where the intercalating ligand is 1,10-phenanthroline or a
phenanthroline derivative and where the ancillary ligand is either achiral (e.g. ethylenediamine) or
chiral (e.g. diaminocyclohexane) show a range of cytotoxicities with a deﬁned structure–activity
relationship. The most cytotoxic are those that contain methylated-phenanthroline ligands and
1S,2S-diaminocyclohexane (S,S-dach) as the ancillary ligand. We have developed a new puriﬁcation
method using Sep-PakR© C-18 reverse phase columns, which means these metal complexes can be made
faster and cheaper compared to published methods. Platinum(II)-based complexes containing
imidazole, pyrrole and b-alanine subunits, that are capable of recognising speciﬁc DNA base-pair
sequences have also been synthesised. These include linear or hairpin polyamide ligands that can
recognise DNA sequences up to seven base-pairs in length and contain single platinum centres capable
of forming monofunctional adducts with DNA. We have now synthesised and characterised, by 1H and
195Pt NMR, ESI-MS and elemental analysis, the ﬁrst dinuclear platinum(II) DNA sequence selective
agent. Finally, using 1H NMR we have examined the encapsulation of our platinum(II)-based DNA
intercalators by cucurbit[6]uril (CB[6]). Encapsulation by CB[6] was found to not signiﬁcantly change
the cytotoxicity of ﬁve platinum(II)-based DNA intercalators, indicating it may have utility as a
molecular carrier for improved drug delivery.
Introduction
Cisplatin, carboplatin and oxaliplatin (Fig. 1) are used to treat
a narrow variety of human cancers, particularly: head, neck,
ovarian, testicular, lung and colorectal cancers.1 Carboplatin is
generally used where treatment by cisplatin is tolerated poorly,
whereas oxaliplatin is used to treat speciﬁc cisplatin-resistant
cancers.2
Fig. 1 The chemical structures of the clinical agents cisplatin, carboplatin
and oxaliplatin.
Unfortunately, cisplatin is restricted in use by high dose limiting
side effects and the intrinsic or acquired resistance cancers
may have to treatment.3 Resistance to cisplatin and similarly to
carboplatin, can result from several mechanisms, and includes:
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decreased cellular uptake/increased drug efﬂux, increased drug
deactivation arising from increased intracellular glutathione con-
centration, and enhanced DNA adduct repair/tolerance.3 More
effective drugs can be developed by (1) lowering the toxic side-
effects by decreasing their reactivity with non-DNA biological
nucleophiles, (2) the use of drug delivery vehicles to target speci-
ﬁcally cancerous cells, leaving normal cells unharmed, (3) increas-
ing the efﬁciency of DNA binding inside the cell, and (4) design
of drugs that form novel adducts with DNA, different to those of
cisplatin, which are still able to prevent DNA transcription and
replication, but are not recognised and removed by DNA repair
proteins.4–11
To this end, our group has been investigating new drugs as well
as macrocyclic compounds capable of acting as molecular hosts
for use as drug delivery vehicles. This includes the synthesis of
platinum(II)-based DNA intercalators;12–18 that act as agents capa-
ble of intercalating into theDNAdouble helix rather than forming
coordinate covalent adducts with DNA, as cisplatin does. We are
also synthesising platinum(II) complexes which are able to bind to
speciﬁc DNA base-pair sequences, for increased DNA binding
afﬁnity.19–21 Finally, we have examined cucurbit[n]urils (CB[n],
where n = 6, 7 or 8) as molecular hosts for our platinum(II)-based
DNA intercalator agents.22 In the interest of driving an informative
DaltonDiscussion, in this paper we discuss our past researchwork
as a foundation for the reporting of our most recent advances in
our drug design and synthesis, and the ability of CB[6] to act
as a molecular host for improved delivery of our platinum DNA
intercalators. We also discuss where we believe platinum(II)-based
drug design and delivery is heading and our plans for the future.
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Experimental
Materials and general methods
Fmoc–lysine–(Fmoc)–OHwas purchased fromAuspep,Australia.
b-Alanine and c-buytric acid were purchased from Fluka. 1S,2S-
Diaminocyclohexane, 1,10-phenanthroline, 3,4,7,8-tetramethyl-
1,10-phenanthroline, 5,6-dimethyl-1,10-phenanthroline and 4,7-
dimethyl-1,10-phenanthroline were purchased from the Aldrich
Chemical Company. Sep-PakR© (2 g) C-18 reverse phase columns
were purchased from Waters. DowexR© anion exchange resin and
5% foetal bovine serumwere obtained from Sigma-Aldrich. Potas-
sium tetrachloroplatinate(II) was purchased from Precious Metals
Online. Dimethyl sulfoxide (D, 99.9%), dimethylformamide (D,
99.9%) and deuterium oxide (D, 99.9%) were purchased from
Cambridge Isotope Laboratories. Cucurbit[6]uril was made as
previously described.23 The heterocyclic 1-methylimidazole and
1-methylpyrrole rings for the polyamide were made as previously
described.19,21
ESI-MS
Positive ion ESI mass spectra were acquired using a Micromass
(Wyntheshawe,UK)QuattroMicroTM spectrometer equippedwith
a Z-spray probe. Solutions containing concentrations ranging
between 10 and 50 lM were injected into the instruments at a
ﬂow rate of 10 lLmin−1. The source and desolvation temperatures
were 150 and 120 ◦C, respectively. The capillary tip potential and
cone voltage were 2500 and 50 V, respectively. Between 10 and 50
acquisitionswere summed to obtain spectra, whichwere calibrated
against a standardCsI solution (750mM)over the samem/z range.
Cytotoxicity assays
Growth inhibition cytotoxicity experiments were performed as
previously described.24
NMR
NMR spectra were obtained on a 300 MHz Varian Mercury or a
400 MHz Bruker Avance spectrometer, in d6-DMSO, d7-DMF or
D2O, referenced internally to the solvent. NMRwere run at 35 ◦C
for DMSO and 25 ◦C for D2O/DMFunless otherwise stated. 195Pt
NMR were externally referenced to K2PtCl4 (−1631 ppm; D2O,
25 ◦C,N = 21.4MHz) at an operating frequency of 85.88MHz.25,26
For one-dimensional spectra, a spectral width of 5000 Hz was
used with 50 000 data points, a d1 of 0.5 s and an acquisition time
of 3 s.
Improved synthesis of platinum(II)-based DNA intercalators
K2PtCl4 (∼0.1–1.0 g) and the ancillary ligand (1 mol. equiv.)
are stirred together at r.t. in water (100 mL). After stirring for
48 h, the resultant yellow precipitate is collected by ﬁltration
and washed with water, ethanol and diethyl ether. The metal
complex [Pt(ancillary ligand)Cl2] (∼0.1–1.0 g) is then reﬂuxed
in water (∼100–500 mL) with the intercalating ligand (1.1 mol.
equiv.) for at least 24 h. The clear, yellow solution is ﬁltered then
concentrated by rotary evaporation to ∼20–50 mL. AWaters (2 g)
C18-reverse phase Sep-PakR© is activated with methanol (10 mL)
and washed with water (20 mL) before the metal complex solution
is loaded onto the column and eluted with water (∼20–30 mL)
as a yellow band, leaving an orange-black band on the head of
the column. The column is then washed with 90% CH3CN–9%
H2O–1% triﬂuoroacetic acid, eluting another yellow band, which
is rotary evaporated to dryness, dissolved in a minimum amount
of water and eluted with water on fresh Sep-PakR©, leaving an
orange band on the head of the column. The two water fractions
are combined and then either lyophilised or rotary evaporated to
dryness (yield 80–90%).
Solid phase synthesis
Machine assisted synthesis was performed on a Symphony
Quartet 3.21 protein synthesiser on a 0.28 mmol scale, as
previously described.21 Each cycle of monomer addition involved
a dichloromethane (DCM) wash, a dimethylformamide (DMF)
wash, deprotection with 20% piperidine–DMF for 3min, draining
the reaction vessel, a DMFwash, deprotection for 17min, a DCM
wash, 2 × DMFwashes, draining the reaction vessel, coupling for
3.5 h (10 h when coupling to an imidazole ring), coupling for 1 h,
and ﬁnally, draining the reaction vessel. Activated transplatin was
coupled to the polyamide in the presence of triethylamine (TEA,
0.27 mL, 2.0 mmol) for 15 h in the dark, after which the resin was
washed with 1 × DMF, 2 × brine, 2 × water, 2 × DMF, 3 × DCM
and dried for 1 h. The activated acids were added manually to the
reaction vessel at the end of every deprotection cycle. The cycle
was interrupted, the reaction vessel vented, and the activated acid
added before the cycle was resumed.
Activation of Fmoc–lysine–(Fmoc)–OH
Fmoc–lysine–(Fmoc)–OH (0.37 g, 0.62 mmol) was dissolved in
DMF (7 mL). o-Benzotriazole-N,N,N ′,N ′-tetramethyl-uronium-
hexaﬂuoro-phosphate (0.21 g, 0.56 mmol) was added followed
by diisopropylethylamine (0.31 mL, 1.8 mmol) and the solution
stirred for 10 min.
Synthesis of DNHLSP-6
The metal complex was prepared by machine-assisted synthesis
protocols. Once synthesised, it was cleaved from the resin by
addition of a solution of DCM (10 mL), triﬂuoroethanol (TFE,
2.4 mL) and acetic acid (1.2 mL) before it was shaken very gently
for 1.5 h. The resin was removed by ﬁltration and washed with
TFE–DCM (1 : 4, 6 mL) before it was subjected to the cleaving
conditions twicemore. The yellow-brownﬁltratewas collected and
the solvent was reduced in volume under pressure to ∼2 mL. Cold
diethyl ether (4 mL) was added and the mixture left in the fridge
for 1.5 h to precipitate a yellow solid. The solvent was decanted
and water (3 mL) was added to the solid before the solution
was lyophilised to yield DNHLSP-6 (0.27 g, 77%) as a brown-
yellow solid. Anal. calc. for C46H71Cl4N23O10Pt2·5H2O: C, 31.97;
H, 4.72,N, 18.64%. Found: C, 31.65;H, 4.65;N, 18.97%. 1HNMR
300 MHz (d6-DMSO): d 10.80 (s, 1H), 9.83 (s, 1H), 9.81 (s, 1H),
9.76 (s, 1H), 9.66 (s, 1H), 9.54 (s, 1H), 8.21 (t, 1H, J = 5.8 Hz),
7.96 (t, 1H, J = 5.4 Hz), 7.64 (s, 1H), 7.62 (s, 1H), 7.51 (s, 2H),
7.21 (d, 1H, J = 1.4 Hz), 7.17 (d, 1H, J = 1.4 Hz), 7.15 (d, 1H,
J = 1.4 Hz), 7.01 (d, 1H, J = 1.4 Hz), 6.85 (d, 1H, J = 1.4 Hz),
6.83 (d, 1H, J = 1.5 Hz), 5.79 (t, 2H), 5.62 (t, 2H), 4.03 (s, 3H),
4.00 (s, 3H), 3.96 (s, 3H), 3.84 (s, 3H), 3.83 (s, 3H), 3.80 (s, 3H),
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3.33 (m, 6H), 2.47 (t, 2H, J = 7.1 Hz), 2.38 (t, 2H, J = 7.5 Hz),
2.29 (t, 2H, J = 7.4 Hz), 1.82 (m, 4H, J = 7.1 Hz), 1.58 (bm, 2H).
195Pt NMR 85 MHz (d7-DMF): d −2424 (bs), −2426 (sh).
Encapsulation of platinum(II)-based DNA intercalators in CB[6]
The metal complexes 56MESS, 47MESS, 3478MESS, 5MESS
and PHENSS (0.01–0.03 g) were added to CB[6] (1 mol. equiv.)
and NaCl (15 to 30 mol. equiv.) in water (∼200 mL) and
heated (60–70 ◦C) until the solution went clear, colourless.
The solution was stirred with heating for a further 3–4 h,
then stirred overnight at room temperature. The solvent was
removed by rotary evaporation or lyophilisation to yield the
products as yellow solids. 3478MESS-CB[6]. Anal. calc. for
C58H66Cl2N28O12Pt·12H2O·15NaCl: C, 25.74; H, 3.35; N, 14.49%.
Found: C, 26.25; H, 3.39; N 13.93%. PHENSS-CB[6]. Anal.
calc. for C54H58Cl2N28O12Pt·12H2O·27NaCl: C, 19.35; H, 2.47; N,
11.70%. Found: C, 19.39; H, 2.50; N, 11.69%. 47MESS-CB[6].
Anal cal. for C56H62Cl2N28O12Pt·3H2O·16NaCl: C, 26.13; H, 2.66;
N, 15.23%. Found: C, 26.49; H, 3.09; N, 15.30%. 5MESS-CB[6].
Anal. calc. for C55H60Cl2N28O12Pt·9H2O·20NaCl: C, 22.76; H,
2.71; N, 13.51%. Found: C, 22.90; H, 2.95; N, 13.55%. 56MESS-
CB[6]. Anal. calc. forC56H62Cl2N28O12Pt.10H2O.29NaCl:C, 19.44;
H, 2.39; N, 11.33%. Found: C, 19.27; H, 2.51; N, 11.32%.
Results and discussion
Platinum(II)-based DNA intercalators
Over the last seven years we have developed over 60 platinum(II)-
based DNA intercalators and examined their utility as anti-
cancer agents, principally through the use of growth inhibition
cytotoxicity assays using the L1210 murine leukaemia cell line
and DNA binding experiments. These agents typically contain
1,10-phenanthroline or phenanthroline derivatives as the inter-
calating ligand and either chiral or achiral ancillary ligands
(Fig. 2).
Previously we have developed a metallointercalator naming
method which uses a ﬁve to eight digit identifying label and allows
easy reference to the metal complexes in text and tables.17 The ﬁrst
one or two numbers indicate the position of substitution on the
phenanthroline ligand, if applicable. The next two or three letters
indicate the substitution group and the ﬁnal two letters indicate
either the chirality of our active 1,2-diaminocyclohexane ligand
or the use of ethylenediamine. For example, [Pt(4,7-dimethyl-1,10-
phenanthroline)(ethylenediamine)]2+ is abbreviated as 47MEEN,
[Pt(5-nitro-1,10-phenanthroline)(1R,2R-diaminocyclohexane)]2+
is 5NORR, [Pt(1,10-phenanthroline)(1S,2S-diaminocyclo-
hexane)]2+ is simply PHENSS and [Pt(5-chloro-1,10-phenan-
throline)(ethylenediamine)]2+ is 5CLEN.
New platinum(II)-based DNA intercalator puriﬁcation method
Previously our preferred method for the synthesis of these DNA
intercalators was by reacting K2PtCl4 with one equivalent of
the intercalating ligand in DMSO, then reﬂuxing the subsequent
[Pt(intercalating ligand)Cl2] complex with two equivalents of
ancillary ligand in water. This method can require numerous pu-
riﬁcation steps, including precipitation fromwater as a perchlorate
salt, then conversion back to the chloride salt with DowexR© anion
exchange resin, and usually further puriﬁcation by liquid–liquid
Fig. 2 The chemical structures of the 1,10-phenanthroline and phenanthroline-based intercalating ligands, and the chiral and achiral ancillary ligands
used during our investigation of platinum(II)-based DNA intercalators as anticancer agents. R = methyl, nitro, amino or chloro. * Indicates a chiral
centre (either S or R). The numbering scheme used for the intercalating ligand protons is shown on 1,10-phenanthroline.
This journal is © The Royal Society of Chemistry 2007 Dalton Trans., 2007, 5055–5064 | 5057
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extraction with toluene. Often, the precipitation and extraction
steps need to be repeated several times to ensure purity. This is
labourious and reduces the yield with each additional puriﬁcation
step.
We can now report a newmethod for synthesis and puriﬁcation.
K2PtCl4 is reacted with one equivalent of ancillary ligand in water.
The subsequent [Pt(ancillary ligand)Cl2] complex is reﬂuxed with
1.1 equivalents of intercalating ligand overnight, to produce a
clear, yellow coloured solution. This solution was then reduced to
a minimum volume without precipitation of the metal complex.
A Waters C18-reverse phase Sep-PakR© (2 g) was activated with
methanol, washed with water and the DNA intercalator solution
loaded onto the column in 10 mL batches. Elution with water
(ca. 20–30 mL) yielded the product which was then lyophilised.
Occassionally, the solution needs to be eluted a second time to
ensure purity. Sep-PakR© columns can be reused for subsequent
batches, once impurities have been removed from the columnusing
90% acetonitrile–9% water–1% triﬂuoroacetic acid. These impure
fractions can also be rotary evaporated to dryness, redissolved
in water and eluted on a fresh Sep-PakR© to yield more product,
increasing the overall yield by as much as 10%.
This newmethod has two advantages. First, it uses less ancillary
ligand, which is generally more expensive than the intercalating
ligand due to the cost of resolving the chiral ligand. Second,
the new method uses just one puriﬁcation step, eliminating the
need to precipitate from solution as perchlorate salts. Additionally,
puriﬁcation of the products by the new method takes between 2
and 4 h depending on the batch size (up to 500 mg), as opposed to
the previous method which took around 1 to 2 weeks to attain the
same level of purity. Larger batch sizes (1 to 2 g) can be completed
if a larger reverse phase Sep-PakR© (i.e. 10 g) is used.
In vitro cytotoxicity
From cytotoxicity growth inhibition assays our three best
platinum(II)-based DNA intercalators are [(5,6-dimethyl-1,
10-phenanthroline )(1S,2S -diaminocyclohexane)platinum(II ) ]2+
(56MESS), [(5-methyl-1,10-phenanthroline)(1S,2S-diamino-
cyclohexane)platinum(II)]2+ (5MESS) and [(1,10-phenanthro-
line)(1S,2S-diaminocyclohexane)platinum(II)]2+ (PHENSS),
although all DNA intercalators tested to date which contain S,S-
dach ancillary ligands display higher cytotoxicity than cisplatin
in the L1210 murine leukaemia cell line (Table 1). Our lead
drug 56MESS is ca. 100-fold more cytotoxic than cisplatin. This
family of DNA intercalators also displays excellent cytotoxicity
Table 1 Cytotoxicity, expressed as IC50 (lM), of our leading platinum(II)-
based DNA intercalators in the L1210 murine leukaemia cell line. IC50 is
deﬁned as the required concentration of drug to inhibit cellular growth by
50%
Metal complex IC50/lM Metal complex IC50/lM
Cisplatin 1.0 47MESS 0.13a
56MESSa 0.0092 5NHSS 0.32b
5MESSb 0.033 DPQSS 0.33b
5CLSSb 0.13 5NOSS 0.57b
PHENSSc 0.13 3478MESS 0.87a
a New data based on previously published28 metal complexes using the
new puriﬁcation method. b Data taken from reference 17. c Data taken
from reference 15.
in a number of human cancer cell lines, including some that are
sensitive to cisplatin treatment and others that have one or more
modes of resistance to cisplatin (see ESI‡). Before the discovery
of 56MESS and 5MESS the complex PHENSS15 was tested in
several human cancer cell lines and displayed potent cytotoxicity
in the A-427 (human lung cancer), RT-112 and RT-4 (human
bladder cancer), KYSR-70 (human oesophagus cancer), SISO
(human cervical cancer), MCF-7 (human breast cancer), 2008
(human ovarian carcinoma), C13*5 (human ovarian carcinoma
with acquired resistance to cisplatin), SKOV-3 (human ovarian
carcinoma with intrinsic resistance to cisplatin), 5637 (bladder
cancer) and 5637/DDP (bladder cancer with acquired resistance
to cisplatin) cell lines.15
From these cytotoxicity tests we have determined a set of
structure–activity rules for this family of metal complexes.15,17 For
high cyotoxicity and the ability to overcome cisplatin resistance the
1,10-phenanthroline ligand should containmethyl groups in either
the ﬁve or both the ﬁve and six positions. Themost active ancillary
ligand is 1,2-diaminocyclohexane (dach). In all cases platinum(II)-
basedDNA intercalators containing the dach ligand in anS,S con-
formation are more cytotoxic than the R,R conformation, in the
cell lines tested.15,17 Achiral ligands (like ethylenediamine) impart
the least cytotoxic potential. Other ancillary ligandswe have exam-
ined include 2R,3R-, 2S,3S- and meso-butane-2,3-diamine, 1R-,
1S- and meso-propane-1,2-diamine, N,N ′-dimethyl-1R-propane-
1,2-diamine, N,N ′-dimethyl-1S-propane-1,2-diamine, and 1S,3R-
and 1R,3S-1,3-diamino-1,2,2-trimethylpentane.13,27
The exact mechanism(s) by which these complexes exert their
cytotoxicity and overcome cisplatin resistance, however, is still not
clear. Their binding to DNA has been studied by molecular mod-
elling, 1H NMR with the oligonucletoide d(GTCGAC)2, and cir-
cular dichroism, UV-Vis and ﬂuoresence studies with calf-thymus
DNA. From these experiments we know that these metal com-
plexes are able to intercalate double stranded DNA with a prefer-
ence for GT/CA sequences with the ancillary ligand in the DNA
minor groove.12–15 Interestingly, there are no signiﬁcant differences
between the DNA binding of the highly cytotoxic (5MESS),
moderately cytotoxic (5MERR) and poorly cytotoxic [(5-methyl-
1,10-phenanthroline)(ethylenediamine)platinum(II)]2+ (5MEEN)
complexes.17 This indicates that either DNA binding is not the
mechanism by which these complexes exert their cytotoxicity, or,
that their DNA binding does induce apoptosis, but their ability to
reach DNA as the cellular target is determined by intracellular
transport factors which differ based on the subtle structural
changes between the active and inactive metal complexes.17 We
are currently completing in vitro cytotoxicity and cellular uptake
studies with 56MESS, 56MERR and 56MEEN in the LoVo
human adenocarcinoma colorectal cancer cell line and hope to
report the results in the near future.
Platinum(II) DNA sequence selective complexes
When 1-methylimidazole (Im), 1-methylpyrrole (Py) and 1-
methylhydroxypyrrole (Hp) heterocyclic rings are coupled into
polyamide linear or hairpin chains they produce compounds that
are capable of recognising and binding speciﬁc DNA base-pair
sequences. Each pair of heterocyclic rings recognises a speciﬁc
base-pair inDNA: Im/Py andPy/Impairings distinguish between
G:C and C:G base pairs respectively, while Hp/Py and Py/Hp
5058 | Dalton Trans., 2007, 5055–5064 This journal is © The Royal Society of Chemistry 2007
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recognise T:A and A:T base pairs. A combination of Py/Py is
selective for both A:T and T:A base pairs.29
To this end we are examining the utility of platinum(II)-
polyamide complexes as agents that will show enhanced DNA
adduct formation compared to cisplatin. The enhanced DNA
afﬁnity will be facilitated through preferential binding to extended
telomere (TTAGGG) sequences commonly found on the ends
of chromosomal DNA in cancer cells.30 Previously, we have syn-
thesised four DNA sequence selective complexes with linear and
hairpin polyamide ligands (Fig. 3). This includes twomononuclear
platinum complexes with linear, three-ring polyamide ligands,
selective for 5′-TGTCA-3′ DNA sequences. These two metal
complexes,DJ1953-2 andDJ1953-6, unwind supercoiledDNAby
Fig. 3 The chemical structures of the ﬁve platinum(II) DNA sequence
selective complexes synthesised using either wet chemistry or solid phase
synthesis. Anions have been omitted for clarity, but are generally chlorides.
13◦, inhibit RNA transcription, form coordinate covalent adducts
with DNA and show a magnitude of order increase in binding
afﬁnity over a double mismatch DNA sequence.20 Unfortunately,
neither metal complex displayed cytotoxicity better than cisplatin
in the L1210 murine leukaemia cell line.
We have also examined the best method of synthesis for more
complex mononuclear platinum complexes with six and eight
ring polyamide hairpin ligands by wet chemistry or solid phase
synthesis.21 Solid phase synthesis is more economical, efﬁcient
and faster than wet chemistry and is the preferred method in our
group for the synthesis of platinum(II) DNA sequence selective
agents.21 We can now report the synthesis and characterisation
of a new dinuclear platinum(II) DNA sequence selective complex,
DNHLSP-6.
DNHLSP-6 was synthesised to determine whether a dinuclear
platinum(II) DNA sequence selective agent would demonstrate
higher cytotoxicity compared to similar mononuclear platinum(II)
complexes. In this case, DNHLSP-6 contains a BBR3005-like
component (a drug already shown to have cytotoxicity better than
cisplatin in sensitive and cisplatin-resistant cell lines),5,6 with two
trans-chloroplatinum groups separated by a 1,5-diaminopentane
chain. It is expected that like BBR3005,DNHLSP-6 is also able to
form ﬂexible, long range, DNA interstrand adducts, which would
be able to bypass removal byDNArepair proteins and thus display
higher cytotoxicity than cisplatin.
The synthesis of DNHLSP-6 was accomplished using an
adaptation of our published solid phase synthesis method by
sequential coupling of Im, Py, c-butyric acid and b-alanine on
a Symphony Quartet Protein Synthesiser (Scheme 1).21 The major
difference was the use of the di-Fmoc–lysine–OH linker instead of
4-(Fmoc–amino)butyric acid. This allows the hairpin polyamide
to coordinate to two individual platinum centres through two
individual amine groups after the removal of bothFmocprotecting
groups.
In the 1H NMR spectrum (see ESI‡) of DNHLSP-6, there are
six amide singlets between 9.54 and 10.8 ppm. The two triplets
at 7.96 and 8.21 ppm correspond to the two amide bonds on
the aliphatic chains. The nine aromatic hydrogens appear as three
singlets and six doublets between 6.83 and 7.64 ppm.The fourNH3
groups attached to the platinum appear as two triplets at 5.62 and
5.79 ppm. The six methyl groups appear as six singlets between
3.80 and 4.03 ppm. The OH of the carboxylic acid at 3.33 ppm is
at the same chemical shift as that of water in d6-DMSO and thus
could not be individually observed. The remaining groups which
consists of 9 × CH2, a CH and 2 × NH2 appear as triplets and
multiplets between 1.82 and 3.5 ppm.
In the 195Pt NMR spectrum, DNHLSP-6 shows a single
platinum resonance at −2424 ppm with a shoulder at a higher
frequency (∼2426 ppm), indicating two chemically similar, but
separate, platinum groups (see ESI‡). The chemical shift is
consistent with similar metal complexes with PtN3Cl coordination
spheres, where N = two trans ammine ligands and one primary
amine ligand.21,31
In the electrospray ionisation mass spectrum of DNHLSP-6,
there are two prominent ion peaks which occur at m/z 784.4
and 1566.4 (see ESI‡). The peak at m/z 784.4 corresponds to the
parent metal complex with a 2+ charge. The peak at m/z 1566.4
corresponds to the deprotonated metal complex with a charge of
+1. Fragmentation ions are also observed. The peak atm/z 1303.1
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Scheme 1 Solid phase synthesis of DNHLSP-6. Each step (except the addition of the platinum) represents the removal of the Fmoc-protecting group
using 20% piperidine followed by coupling of the rings or linker.
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can be assigned to the metal complex with a 1+ charge from the
loss of one trans-chlorodiammine platinum group.
Elemental analysis shows that despite DNHLSP-6 not dis-
playing any solubility in water (it is soluble only in DMF and
DMSO) the solid produced by lypholisation contains ﬁve waters
of crystallisation.
The cytotoxicity of DNHLSP-6 is currently being examined
using growth inhibition assays in a variety of human cancer cell
lines.
Cucurbit[n]urils as drug delivery vehicles
Like the clinical agents cisplatin, carboplatin and oxaliplatin
both our platinum(II)-based DNA intercalator complexes and
our platinum(II) DNA sequence selective complexes are expected
to exhibit high dose limiting side-effects. Primarily, these side-
effects occur because platinum chemotherapeutic drugs do not
discriminate well between normal and cancerous cells. As such,
we are examining ways of speciﬁcally delivering our platinum(II)-
based drugs only to cancerous cells, using novel drug delivery
vehicles.
Cucurbit[n]urils (CB[n], where n = 5, 6, 7, 8 or 10), are small
barrel shaped molecules that have an internal hydrophobic cavity
and symmetrical, hydrophilic portals and have been shown as
suitable molecular hosts for neutral and charged mono- and
multinuclear platinum(II) anticancer agents (Fig. 4).32–34
Fig. 4 The chemical structure of cucurbit[6]uril (CB[6]).
Previously, we have studied the encapsulation of the metallo-
intercalators [(5-chloro-1,10-phenanthroline)(1S,2S-diamino-
cyclohexane)platinum(II)]2+ (5CLSS), [(5-chloro-1,10-phenanthro-
line)(1R,2R-diaminocyclohexane)platinum(II)]2+ (5CLRR) and
[(5-chloro-1,10-phenanthroline)(ethylenediamine)platinum(II)]2+
(5CLEN) with CB[6], CB[7] and CB[8].22 All three platinum(II)-
based DNA intercalators are bound over the ancillary ligand with
slow to intermediate exchange kinetics on theNMRtimescale. The
different sized cucurbiturils are found to affect the cytotoxicity
in a size speciﬁc manner, CB[7] and CB[8] encapsulation resulted
in a dramatic unwanted decrease in cytotoxicity but interestingly
CB[6] was found to increase the cytotoxicity of 5CLSS by
2.5-fold.22 Therefore it was of interest to determine whether CB[6]
would also increase the cytotoxicity of other S,S-dach containing
platinum(II)-based DNA intercalators.
We can now report on the encapsulation by CB[6] of
ﬁve of our platinum(II)-based DNA intercalators, 56MESS,
5MESS, [(3,4,7,8-tetramethyl-1,10-phenanthroline)(1S,2S-
diaminocyclohexane)platinum(II)]2+ (3478MESS), [(4,7-dimethyl-
1,10-phenanthroline)(1S,2S-diaminocyclohexane)platinum(II)]2+
(47MESS) and PHENSS, and their subsequent cytotoxicity in
the L1210 murine leukaemia cell line. The metallointercalators
were chosen because of the different position and number of
methyl groups on the phenanthroline ligand, which provide
alternate and competing binding sites for CB[6] encapsulation
of the ancillary ligand, and because of the range of the metal
complexes’ cytotoxicities.
Unfortunately, CB[6] is relatively insoluble in aqueous solutions
(<1 mM) and requires the use of alkali earth metals such as
caesium, sodium or lithium (∼20 mM) for concentrations high
enough to study host–guest interactions by NMR. As such, in
this study it was necessary to dissolve both the platinum(II)-
based DNA intercalators and CB[6] with between 15 and 20
equivalents of NaCl. NaCl was chosen in preference to CsCl or
LiCl as saline solutions are routinely used todeliver platinumdrugs
intraveneously in the clinic. When 56MESS, 5MESS, 47MESS or
PHENSS are added to 0.1 to 1.1 equivalents of CB[6] there are
signiﬁcant and speciﬁc shifts of the metal complex resonances
in the 1H NMR spectra (see Fig. 5). The S,S-dach resonances
shift to a lower frequency between 0.5 to 1.0 ppm, whilst the
phenanthroline resonances move slightly to a higher frequency
or are not affected. Previous research has established that shifts
to lower frequencies (upﬁeld) are observed for protons of guest
compounds shielded inside the cucurbituril cavity32 and shifts
to higher frequencies (downﬁeld) are observed for those guest
protons deshielded by being outside, but close to, the cucurbituril
portals.32 These results therefore clearly indicate that for 56MESS,
5MESS, 47MESS and PHENSS, CB[6] encapsulates the metal
complexes over the S,S-dach ligand (Fig. 6). The 1HNMR spectra
also demonstrate that this encapsulation process is slow on the
NMR timescale. When 0.5 equivalent of CB[6] is added to the
metal complexes, resonances representing free and bound metal
complex are observed simultaneously (see Fig. 5).
An interesting feature of the 1H NMR spectra are the double
set of resonances for the Ha and Hb CB[6] protons, but only a
single methine resonance. The portal diameter of CB[6] is smaller
than the width of S,S-dach, and as such, one of the portals has to
stretch to accommodate the ligand within the cavity. As such, the
two portals would no longer be equivalent and thus lead to the
extra set of CB[6] resonances observed. Interestingly, the amine
resonances of these metal complexes display signiﬁcant shifts to
lower frequencies of ca. 0.6 to 0.75 ppm. These lower frequency
shifts are indicative that they are located within the CB[6] cavity,
most likely hydrogen bonding with the oxygens of one of the
portals. This hydrogen bonding could also explain the extra set
of Ha and Hb CB[6] resonances. Importantly, when dissolved in
D2OwithoutCB[6] the amine resonances of the platinum(II)-based
DNA intercalators exchange with the solvent within 1–2 min, but
with an equimolar concentration of CB[6], the amine resonances
are still observable one to two weeks after dissolution. This
indicates that theCB[6]–metal complex species is particularly long-
lived and that encapsulation by CB[6] greatly increases the steric
hinderance of nucleophiles toward the platinum atom as the entire
S,S-dach ligand is located in the CB[6] cavity.
When the platinum(II)-based DNA intercalators and CB[6] are
combined in a ratio of 1 : 1 (as measured by resonance integration)
the 1H NMR spectra indicate that two species of metal complex
are present. The major species represents full encapsulation of the
S,S-dach ligand within CB[6], with a second set of metal complex
resonances representing free metal complex. As stated previously,
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Fig. 5 1H NMR spectra of (a) 47MESS in D2O and (b) 47MESS with 0.5 equivalent of CB[6] in ∼20 mM NaCl, showing both free and bound metal
complex resonances and the large shifts to a lower frequency of the S,S-dach amine and aliphatic protons, which is evidence of the ancillary ligand being
located within the CB[6] cavity. These spectra are indicative of similar spectra for 56MESS, 5MESS and PHENSS with CB[6].
Fig. 6 A schematic diagram showing the exchange process between a
free platinum(II)-based DNA intercalator (PHENSS) and where it is
encapsulated over the ancillary ligand by a CB[6] molecule. Anions and
charges have been omitted for clarity.
it is likely that one of the CB[6] portalsmust stretch to permit entry
of the S,S-dach ligand, and therefore there is a thermodynamic
cost to do so. As such, at any given moment there appears
to be an equilibrium between free and bound metal complex,
where the ratios of each are approximately 10 and 90%, respec-
tively. Unfortunately, efforts to determine the binding constants
and/or exchange rate of the DNA intercalator–CB[6] complex
by UV-Vis, circular dichroism and exchange NMR have been
unsuccessful.
When 3478MESS is added to an equimolar concentration of
CB[6], three sets of CB[6] resonances are observed in the 1H
NMR.We assign these to three different species, in slow exchange,
between free CB[6], CB[6] bound around S,S-dach and CB[6]
bound around the methyl groups of the 3,4,7,8-Me4phen ligand
(Fig. 7).
In the aliphatic regionof 3478MESS, two sets of phenanthroline
methyl resonances were observed (four peaks in total). One set of
resonances are from the methyl groups being deshielded inside
the CB[6] cavity (A). The other resonances result from the two
remaining species; the free metal complex (C) and the metal
complex with CB[6] bound over S,S-dach (B) (see Fig. 7).
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Fig. 7 Aschematic diagramdisplaying the three proposedmodes ofCB[6]
encapsulation of 3478MESS. Anions and charges have been omitted for
clarity.
Two sets of S,S-dach resonances were also observed in the
aliphatic region. One set results from CB[6] encapsulation over
the ancillary ligand (B), and the other set of resonances resulted
from the other two species; free metal complex (C) and the metal
complex with CB[6] encapsulated over two phenathroline methyl
groups (A). These latter two species have equivalent S,S-dach
proton resonance chemical shifts, due to the CB[6] having little
effect on their chemical environments. Five resonances integrating
to a total of six protons were observed in the aromatic region of
the 3478MESS 1H NMR spectrum. These protons could not be
assigned as the degree of shifting of each signal in each binding
mode was unknown, however the spectra did conﬁrm that there
were indeed three different species of platinum(II)-based DNA
intercalator in the solution.
Elemental analysis indicates that at a ratio of 1 : 1 platinum(II)-
based DNA intercalator to CB[6], all complexes contain waters
of crystallisation. 3478MESS and PHENSS both precipitate with
12 water molecules, 47MESS with three water molecules, 5MESS
with nine and 56MESS with 10 waters of hydration. These results
are not unexpected however, as all cucurbit[n]urils are known,
from X-ray crystal structures, to readily form hydrated solids.23
CB[5–10] typically form solids with between eight and 30 waters
of hydration, and sometimes acids (typically HCl) as well.23
The platinum(II)-based DNA intercalators 56MESS, 5MESS,
47MESS, 3478MESS, PHENSS and 5CLSS were tested for
cytotoxicity in the absence and presence of one mole equivalent of
CB[6] (Table 2). For 5CLSS and 3478MESS CB[6] encapsulation
resulted in a small increase in cytotoxicity, 56MESS, 47MESS and
PHENSSdisplay a small decrease in cytotoxicity, whereas 5MESS
displays no signiﬁcant change (within experimental error). These
results indicate that because CB[6] does not signiﬁcantly change
Table 2 Cytotoxicity, expressed as IC50 (lM), of our methyl-group
containing platinum(II) DNA intercalators withCB[6] in the L1210murine
leukaemia cell line. IC50 is deﬁned as the required concentration of drug
to inhibit cellular growth by 50%. Values were determined from between
3 and 5 experiments, and reported ± standard errors
Metal complex IC50 free drug/lM IC50 with CB[6]/lM
Cisplatin 1.0 n/a
56MESS 0.0092 ± 0.0008 0.011 ± 0.004
5MESS 0.033a ± 0.014 0.038 ± 0.02
47MESS 0.13 ± 0.01 0.17 ± 0.01
5CLSSb 0.13 ± 0.003 0.05 ± 0.008
PHENSS 0.25 ± 0.02 0.41 ± 0.01
3478MESS 0.87 ± 0.03 0.60 ± 0.05
a Data taken from reference 17 b Data taken from reference 22.
the cytotoxicity of these platinum(II)-based DNA intercalators, it
may have utility as a molecular host for improved drug delivery.
Future work
Our future work continues to develop further our family of
platinum(II)-based DNA intercalators. This includes new inter-
calating ligands like pyridocarbazole,35 other chiral ancillary
ligands like 1R,2R-, 1S,2S- andmeso-1,2-bis(4-ﬂuorophenyl)-1,2-
ethanediamine, and the replacement of the central platinum atom
with other square-planar transition metals, such as palladium(II).
We are also working towards expanding our platinum(II) DNA
sequence selective family of metal complexes by creating water
soluble multinuclear complexes. One such compound includes a
trinuclear platinum complex where the terminal platinum groups
are linked to the central platinum group through two separate
hairpin polyamides. This complex will have a 4+ charge and be
capable of recognising DNA sequences up to 12 base pairs in
length; speciﬁcally this will mean the compound would be capable
of recognising and binding tandem duplex telomere sequences,
d(TTAGGGTTAGGG).
Despite our good results with cucurbiturils, their use is limited
by their poor water solublity and their ability to transport only one
drug molecule at a time. We are therefore examining other molec-
ular hosts such as cyclodextrins, calix[n]arenes and dendrimers.
These additional molecular hosts will allow us to examine in detail
several different factors thatmay affect drug transport and release;
i.e. ﬂexible vs rigid structure, chiral vs achiral, sub-nanometre vs
nanometre size, and water solubility/lipophilicity. We also plan
to examine the cellular uptake and distribution of cucurbit[n]urils
(where n = 6, 7 or 8) in order to better understand how they affect
drug cytotoxicity. With this information we hope to be able to
design a molecular host that will not only transport drugs to, and
within, the cell, preventing their degradation and deactivation, but
also develop molecular hosts that can speciﬁcally recognise and
bind cancerous cells.
Conclusions
In this paper we have discussed the three main thrusts of
our research into improved platinum(II)-based anticancer drug
design and delivery. From a family of over 60 platinum(II) DNA
intercalator drugs, one metal complex 56MESS displays up to
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100-fold better cytotoxicity compared to cisplatin in the L1210
murine leukaemia cell line.
We have synthesised ﬁve platinum(II)-based DNA sequence
selective agents, including a new dinuclear platinum(II) complex.
These compounds form the basis of further drug design of
more complex, water soluble platinum(II)-based DNA sequence
selective agents capable of enhanced DNA sequence recognition
and higher cytotoxicity. Finally, our platinum(II)-based DNA
intercalators are encapsulated over the ancillary ligand by CB[6],
and despite the presumed strong binding, have little, to no, affect
on the metal complexes’ cytotoxicity. These results form the basis
of our ﬂedgling drug delivery research and we plan to expand this
work to othermolecular hosts such as cyclodextrins, calix[n]arenes
and dendrimers.
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